Health economic outcomes of a minimal monitoring approach to providing HCV therapy.

ABSTRACT:

Background

The ACTG A5360 trial demonstrated that HCV treatment without planned on-treatment monitoring is safe and effective. We report the health economic outcomes of MINMON.

Methods

A5360 was a 5-country, single-arm trial providing sofosbuvir/velpatasvir to people with HCV infection with no planned clinic visits between treatment initiation and week 24 sustained virologic response (SVR) evaluation. Trial records included planned/and most unplanned lab tests and visits. Participants completed a 4-week recall questionnaire at weeks 0, 24, 48, and 72 reporting hospital nights, emergency department visits, and ambulatory visits. We tabulated consumption and multiplied units of consumption by country-specific cost. We report the cost and cost per SVR of MINMON (2020 US$) from

SUBMITTER: Linas BP 

PROVIDER: S-EPMC12014070 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature